NASDAQ · Biotechnology · USD
Purple Biotech Ltd (PPBT) Stock Analysis
Purple Biotech Ltd (PPBT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
PPBT Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.09
- Previous Close
- $1.09
- Day's Range
- 1.09–1.15
- 52-Week Range
- 1.07–14.10
- Volume
- 9.88K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.55
Valuation
- Market Cap
- $1.87M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −47.64
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$26.39M
- Shares Outstanding
- 1.63M
- 1-Year Return
- −80.03%
Dividend and dates
- Avg Volume
- 1.28M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, PPBT closed at $1.15, −80.03% over 1 year.
Purple Biotech Ltd (PPBT) has a market capitalization of $1.87M.
In fiscal 2025, PPBT reported revenue of $0.00.
PPBT Stock Return by Calendar Year
Purple Biotech Ltd (PPBT) 10-year return: what $10,000 became
- 1 year
- $10,000 $1,997
- −80.03%
- 5 years
- $10,000 $12
- −99.88%
- 10 years
- $10,000 $1
- −99.99%
If you had invested $10,000 in Purple Biotech Ltd (PPBT) 10 years ago, at the close on October 21, 2016, it would have been worth $1 at the close on October 21, 2026: −99.99% in total, −58.67% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −82.52% |
| 2025 | −85.97% |
| 2024 | −69.94% |
| 2023 | −43.48% |
| 2022 | −64.52% |
| 2021 | +2.10% |
| 2020 | −51.15% |
| 2019 | +18.18% |
| 2018 | −71.05% |
| 2017 | −26.69% |
| 2016 (partial year) | −8.53% |
As of October 21, 2026.
PPBT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$26.39M | — |
| 2024 | $0.00 | −$7.24M | — |
| 2023 | $0.00 | −$19.88M | — |
| 2022 | $0.00 | −$21.67M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$6.98M | −$26.39M | — |
| 2024 | $0.00 | — | −$10.80M | −$7.24M | — |
| 2023 | $0.00 | — | −$22.27M | −$19.88M | — |
| 2022 | $0.00 | — | −$22.60M | −$21.67M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection
InvestorsHubWhy Is Purple Biotech Stock Gaining Wednesday?
BenzingaPurple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models
BenzingaHC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17
BenzingaCORRECTION: Purple Biotech Q2 EPS $(0.41) Beats $(0.98) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B